Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416598 | 0.82 | TSPO (0.42) | LTA4HTSPOTACR1TEAD3HCRTR1 | |
| SCHEMBL420135 | 0.82 | TSPO (0.41) | TSPO | |
| SCHEMBL28254010 | 0.82 | HTR6 (0.38) | LTA4HTSPOHTR6SIGMAR1TEAD3 | |
| SCHEMBL416578 | 0.81 | TSPO (0.42) | TSPOTACR1TEAD3HCRTR1HCRTR2 | |
| SCHEMBL460215 | 0.80 | TSPO (0.56) | TSPO | |
| SCHEMBL6688729 | 0.71 | TSPO (0.43) | TSPOHTR6HCRTR1HCRTR2 | |
| SCHEMBL6693579 | 0.71 | FABP4 (0.44) | TSPOHTR6HCRTR1HCRTR2 | |
| SCHEMBL12748236 | 0.71 | TSPO (0.44) | TSPO | |
| SCHEMBL12748241 | 0.71 | TSPO (0.44) | TSPO | |
| SCHEMBL12748249 | 0.70 | TSPO (0.43) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | IDO1, IDO2, TPH1 | LTA4H 3561/4885TSPO 3643/4885TACR1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.